The Separate Hypolipoproteinemic Effects of Dextrothyroxine and Ethyl Chlorophenoxyisobutyrate

Publisher Website
Google Scholar
Abstract
D-Thyroxine lowers principally the Sf° 0–20 lipoprotein class as do other thyroid-active substances; whereas Atromid, a mixture of androsterone and ethyl chlorophenoxyisobutyrate (CPIB) lowers principally the Sf° 20–400 class. In addition, the major high density lipoprotein class HDL-3 is lowered by thyroid-active substances but appears to be increased by CPIB. These divergent effects on the serum lipoprotein spectrum are demonstrated in a series of 14 patients and indicate that the lipid-lowering effect of CPIB is different from that of thyroid-active substances. Atromid, with CPIB as its active ingredient, appears to be a promising substance specifically for the treatment of Sf° 20–400 hyperlipoproteinemias.

This publication has 5 references indexed in Scilit: